Search Within

Hematologic Malignancies, Division of

Formats
  1. Meeting Abstract (6372)
  2. Journal Article (5781)
  3. Review (421)
  4. Editorial (196)
  5. Book Section (188)
  6. Research Letter (179)
  7. Guidelines (88)
  8. Conference Paper (65)
  9. Correspondence (62)
  10. Miscellaneous (18)
  11. Book Whole (9)
Groups
  1. Department of Medicine (13278)
  2. Center for Hematologic Malignancies (10612)
  3. GSK Faculty (4482)
  4. Adult Leukemia (3673)
  5. Bone Marrow Transplant (2848)
  6. Lymphoma (2705)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (943)
  3. Ross Levine (787)
  4. Andrew Zelenetz (784)
  5. Steven Horwitz (669)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (340)
  2. 2024 (823)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3529)
  2. Journal of Clinical Oncology (1233)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (330)
  5. Haematologica (292)
  6. Bone Marrow Transplantation (239)

More Publications

Publishers
  1. American Society of Hematology (3806)
  2. Elsevier Inc. (1530)
  3. American Society of Clinical Oncology (1288)
  4. Nature Publishing Group (1009)
  5. American Association for Cancer Research (641)
  6. Wiley Blackwell (433)

More Publishers

Results (13379)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy
    Editorial

    Luttwak, E.; Smith, M. R.; Zelenetz, A. D.
    Expert Opinion on Pharmacotherapy (2023)

    Fulltext@MSK | Save
  • Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients
    Journal Article

    Mahmood, S. S.; Riedell, P. A.; Feldman, S.; George, G.; Sansoterra, S. A.; Althaus, T.; Rehman, M.; Mead, E.; Liu, J. E.; Devereux, R. B.; more...
    European Heart Journal (2023)

    Fulltext@MSK | Save
  • Need for risk adjustment in comparative effectiveness and cost-effectiveness studies in r/r follicular lymphoma
    Correspondence

    Gribben, J.; Palomba, M. L.; Patel, A. R.; Nahas, M.; Neelapu, S. S.
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma
    Research Letter

    Santoro, A.; Moskowitz, A. J.; Ferrari, S.; Carlo-Stella, C.; Lisano, J.; Francis, S.; Wen, R. C.; Akyol, A.; Savage, K. J.
    Blood (2023)

    Fulltext@MSK | Save
  • Patient characteristics and outcomes of outpatient tisagenlecleucel recipients for B cell non-Hodgkin lymphoma
    Review

    Ahmed, N.; Wesson, W.; Mushtaq, M. U.; Porter, D. L.; Nasta, S. D.; Brower, J.; Bachanova, V.; Hu, M.; Nastoupil, L. J.; Oluwole, O. O.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome
    Journal Article

    Hines, M. R.; Knight, T. E.; McNerney, K. O.; Leick, M. B.; Jain, T.; Ahmed, S.; Frigault, M. J.; Hill, J. A.; Jain, M. D.; Johnson, W. T.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • Report of consensus panel 7 from the 11th International Workshop on Waldenström Macroglobulinemia on priorities for novel clinical trials
    Conference Paper

    Tam, C. S.; Kapoor, P.; Castillo, J. J.; Buske, C.; Ansell, S. M.; Branagan, A. R.; Kimby, E.; Li, Y.; Palomba, M. L.; Qiu, L.; more...
    W.B. Saunders Co-Elsevier Inc. (2023)

    Fulltext@MSK | Save
  • Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
    Journal Article

    Atallah, E.; Mauro, M. J.; Hochhaus, A.; Boquimpani, C.; Minami, Y.; Maheshwari, V. K.; Saini, L.; Corbin, R.; Réa, D.
    Journal of Cancer Research and Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Treatment of adult T-cell leukemia/lymphoma: Established paradigms and emerging directions
    Review

    Stuver, R.; Horwitz, S. M.; Epstein-Peterson, Z. D.
    Current Treatment Options in Oncology (2023)

    Fulltext@MSK | Save
  • Progression-free survival and safety at 3.5 years of follow-up: Results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer
    Journal Article

    González-Martín, A.; Pothuri, B.; Vergote, I.; Graybill, W.; Lorusso, D.; McCormick, C. C.; Freyer, G.; Backes, F.; Heitz, F.; Redondo, A.; more...
    European Journal of Cancer (2023)

    Fulltext@MSK | Save